Cell Culture Technology– category –
-
UniXell Biotechnology Secures FDA IND Clearance for iPSC Parkinson’s Therapy UX-DA003, Achieving Dual Breakthrough in China and U.S.
BioInformant China Overview UniXell Biotechnology has secured FDA IND clearance for UX-DA003, an iPSC-derived Parkinson's disease therapy, marking a dual breakthrough in both China and the U.S. UX-DA003 is an allogeneic iPSC-derived midb... -
6th iPSC Drug Development Summit to Address GMP Scale-Up Challenges, Focusing on Gene Editing Safety and QC Frameworks
BioInsights International Overview The 6th iPSC Drug Development Summit will primarily focus on challenges associated with scaling iPSC platforms to GMP standards. Key discussions will cover implementing GMP-compatible gene editing strat... -
FUJIFILM Biotechnologies Drives $7 Billion Expansion in US and Europe, Quadrupling iPSC Production Capacity and Automating with AI
Drug Discovery and Development USA Overview FUJIFILM Biotechnologies is leading a $7 billion expansion across the US and Europe, with FUJIFILM Cellular Dynamics opening a new iPSC manufacturing headquarters to quadruple cell production c... -
PAK BioSolutions’ GMP Purification System Supports First-in-Human Trial Filing, Achieves 4x Faster Production Than Existing Facilities
FirstWord Pharma International Overview A major biopharmaceutical company has filed its first-in-human (FIH) trial, supported by PAK BioSolutions' GMP purification system. This PAK system utilizes a continuous manufacturing approach, cap... -
NTHRYS Achieves 40% Cost Reduction in Dual Antigen CAR-T Manufacturing, Offers Off-the-Shelf NK Cell Expansion Services
NTHRYS International Overview NTHRYS has successfully reduced manufacturing costs for dual antigen CAR-T cell scale-up by 40% while accelerating time-to-clinic. Furthermore, the company now offers clinical-grade NK cell expansion and cry... -
CAR-T’s Geography Problem: Manufacturing Bottlenecks Limit Access, Advances in Closed Systems and Bioprocessing are Key
pharmaphorum UK Overview CAR-T cell therapy's geographical accessibility is heavily dependent on its manufacturing process, with production costs, turnaround times, and available facilities directly impacting patient access. A critical b... -
Closed-System Semi-Automated Manufacturing Key to Expanding CAR-T Access in Low- and Middle-Income Countries by Reducing Cost and Complexity
PubMed International Overview CAR-T cell therapy adoption in low- and middle-income countries (LMICs) has been severely constrained by high costs, insufficient infrastructure, and complex regulatory demands. However, the advent of closed... -
ProBio’s AAV Manufacturing Excellence Accelerates UC Irvine and GlyTR Therapeutics’ Pan-Cancer CAR-T Program, Achieving 80% CAR Gene Insertion Efficiency
University of California, Irvine USA Overview ProBio's advanced AAV manufacturing technology is critically powering pre-IND research for the first-in-class pan-cancer CAR-T program developed by UC Irvine and GlyTR Therapeutics. ProBio's ... -
KELI Therapeutics Launches Integrated GMP Manufacturing Platform for Orthopedics, Nephrology, and Immunology, Cutting Development Costs and Accelerating Approvals
KELI Therapeutics Europe Overview KELI Therapeutics has successfully deployed a unified GMP manufacturing platform supporting five active cell therapy programs across orthopedics, nephrology, and immunology. This strategic consolidation ... -
Market Report: Global Single-Use Bioreactor Market to Surge, Thermo Fisher and AGC Biologics Expand Capacity
GlobeNewswire Global Overview This article summarizes the market research report "Global Single-use Bioreactors Market Forecast to Surge from USD 3.61 Billion in 2025 to USD 15.11 Billion by 2034." The global single-use bioreactors marke...
